Biogen (BIIB) Misses Q4 EPS by 23c, Offers Guidance
Tweet
Share
E-mail
Get Alerts BIIB Hot Sheet
Price: $209.83 -0.39%
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
SVBT, ZEO, OTLK, More
Financial Fact:
Income before income tax expense: 1.37B
Today's EPS Names:
SVBT, ZEO, OTLK, More
Join SI Premium – FREE
Biogen (NASDAQ: BIIB) reported Q4 EPS of $2.95, $0.23 worse than the analyst estimate of $3.18. Revenue for the quarter came in at $2.4 billion versus the consensus estimate of $2.47 billion.
GUIDANCE:
Biogen sees FY2024 EPS of $15.00-$16.00, versus the consensus of $15.64.
For earnings history and earnings-related data on Biogen (BIIB) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Wolfe Research Upgrades Biogen (BIIB) to Outperform
- Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
- Pro Diversity Network (IPDN) Reports Q2 Loss of $0.15
Create E-mail Alert Related Categories
Earnings, Guidance, Hot Earnings, Hot GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
